|
|
| | YBSJFWOBGCMAKL-PKHQNOSGSA-N Basic information |
| | YBSJFWOBGCMAKL-PKHQNOSGSA-N Chemical Properties |
| form | Solid | | color | White to off-white |
| | YBSJFWOBGCMAKL-PKHQNOSGSA-N Usage And Synthesis |
| Uses | Dabigatran-d4 is deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM)[1][2]. | | References | [1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. DOI:10.1177/1060028018797110
[2] Hauel NH, et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem. 2002 Apr 25;45(9):1757-66. DOI:10.1021/jm0109513
[3] Wienen W, Stassen JM, Priepke H, In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally activeprodrug, dabigatran etexilate. Thromb Haemost. 2007 Jul;98(1):155-62. PMID:17598008
[4] Wienen W, et al. Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats. Thromb Haemost. 2007 Aug;98(2):333-8. PMID:17721615 |
| | YBSJFWOBGCMAKL-PKHQNOSGSA-N Preparation Products And Raw materials |
|